RAB9A

Across TCGA pan-cancer cohorts, RAB9A RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RAB9A’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RAB9A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RAB9A is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

LIHC, THCA, and HNSC are the cancer types where RAB9A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAB9A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	III,IV	+0.926	<.001	9	view →
THCA	Female	All	−0.419	<.001	9	view →
HNSC	All	All	+0.344	.001	8	view →
COAD	All	II,III,IV	−0.419	<.001	6	view →
BRCA	Female	II,III,IV	−0.226	<.001	4	view →
CHOL	Female	All	+2.303	<.001	3	view →
KIRC	All	All	+0.191	.012	3	view →
ESCA	All	All	+0.651	.014	2	view →
LUAD	All	III,IV	−0.321	.016	2	view →
READ	All	All	−0.427	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RAB9A–LIHC

Open the LIHC breakdown →